Compare · BTX vs REPL
BTX vs REPL
Side-by-side comparison of BlackRock Technology and Private Equity Term Trust (BTX) and Replimune Group Inc. (REPL): market cap, price performance, sector, and recent activity on the wire.
Summary
- REPL is the larger of the two at $2.08B, about 1.1x BTX ($1.87B).
- REPL has been more active in the news (12 items in the past 4 weeks vs 1 for BTX).
- REPL has more recent analyst coverage (25 ratings vs 2 for BTX).
- Company
- BlackRock Technology and Private Equity Term Trust
- Replimune Group Inc.
- Price
- -
- -
- Market cap
- $1.87B
- $2.08B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 1
- 12
- Recent ratings
- 2
- 25
BlackRock Technology and Private Equity Term Trust
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
Replimune Group Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Latest BTX
- Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
- Amendment: SEC Form N-CEN/A filed by BlackRock Technology and Private Equity Term Trust
- Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
- SEC Form 3 filed by new insider Mahoney Francis C.
- Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds
- SEC Form N-CSRS filed by BlackRock Technology and Private Equity Term Trust
- Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
- SEC Form N-PX filed by BlackRock Technology and Private Equity Term Trust
- SEC Form 3 filed by new insider Park Charles
- Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
Latest REPL
- Director Slattery Joseph P sold $113,360 worth of shares (5,200 units at $21.80), decreasing direct ownership by 78% to 1,467 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Replimune Group Inc.
- SEC Form 144 filed by Replimune Group Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Replimune Group Inc.
- Amendment: SEC Form 10-Q/A filed by Replimune Group Inc.
- Director Dhingra Kapil exercised 43,169 shares at a strike of $1.75 and sold $408,500 worth of shares (21,500 units at $19.00) (SEC Form 4) to cover taxes
- SEC Form 144 filed by Replimune Group Inc.
- SEC Form 144 filed by Replimune Group Inc.
- SEC Form 10-Q filed by Replimune Group Inc.
- SEC Form 8-K filed by Replimune Group Inc.